{"id":"W2550696258","doi":"10.1093/eurheartj/ehw570","title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","year":2016,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; Servier; Alnylam Pharmaceuticals; AstraZeneca; Amgen","keywords":"Medicine; Valsartan; Enalapril; Sacubitril; Heart failure; Sacubitril, Valsartan; Blood pressure; Cardiology; Internal medicine; Ejection fraction; Hazard ratio; Clinical endpoint; ACE inhibitor; Angiotensin-converting enzyme; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002078568,0.0005208344,0.001031183,0.0002316904,0.0001669467,0.0004544223,0.0004019519,0.0004463681,0.001088786],"category_scores_gemma":[0.001305593,0.0001669432,0.001409723,0.0002406759,0.0002402548,0.0003950933,0.0003581276,0.0009889209,0.0001470845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000451864,"about_ca_system_score_gemma":0.000796591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141941,"about_ca_topic_score_gemma":0.002782843,"domain_scores_codex":[0.9994121,0.0002862196,0.00004217055,0.00007258911,0.00009970603,0.00008729571],"domain_scores_gemma":[0.9989079,0.0002286769,0.0002781163,0.00008243178,0.0001390936,0.0003637238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.525809,0.01231913,0.2844726,0.001494247,0.01163743,0.0001978964,0.0001850365,0.001258637,0.01072235,0.0002798513,0.003576309,0.1480475],"study_design_scores_gemma":[0.08469259,0.08932234,0.8135194,0.0001164932,0.006453204,0.00028648,0.0001233416,0.001610403,0.001312967,0.0004386551,0.00206987,0.00005423291],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958692,0.002500696,0.00008301932,0.0003274787,0.00003584865,0.00005288309,0.0004213788,0.000007459813,0.0007019746],"genre_scores_gemma":[0.9971656,0.0006813076,0.0003171815,0.0003994421,0.0001443808,0.00007095104,0.0009352934,0.000003007224,0.0002828198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002078568,"threshold_uncertainty_score":0.01099265,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01375539312246582,"score_gpt":0.2399470154632738,"score_spread":0.226191622340808,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}